Delayed
TEL AVIV STOCK EXCHANGE
|
5-day change
|
1st Jan Change
|
- ILa
|
-.--%
|
|
-2.55%
|
-3.73%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,031
|
6,104
|
5,204
|
4,590
|
4,361
|
3,753
|
-
|
-
|
Enterprise Value (EV)
1 |
10,046
|
9,028
|
6,859
|
8,096
|
7,683
|
6,962
|
6,765
|
6,566
|
P/E ratio
|
48.3
x
|
-37.6
x
|
-74.8
x
|
-32.8
x
|
-358
x
|
-19
x
|
172
x
|
24.1
x
|
Yield
|
1.59%
|
2.01%
|
2.47%
|
3.05%
|
3.39%
|
4%
|
4.26%
|
4.59%
|
Capitalization / Revenue
|
1.45
x
|
1.21
x
|
1.26
x
|
1.03
x
|
0.94
x
|
0.81
x
|
0.78
x
|
0.75
x
|
EV / Revenue
|
2.08
x
|
1.78
x
|
1.66
x
|
1.82
x
|
1.65
x
|
1.51
x
|
1.4
x
|
1.31
x
|
EV / EBITDA
|
11.2
x
|
10.2
x
|
11.9
x
|
14
x
|
11.6
x
|
9.72
x
|
8.34
x
|
7.72
x
|
EV / FCF
|
40.2
x
|
19.4
x
|
1,715
x
|
38.4
x
|
25.3
x
|
14.9
x
|
13.2
x
|
12
x
|
FCF Yield
|
2.49%
|
5.16%
|
0.06%
|
2.61%
|
3.95%
|
6.71%
|
7.55%
|
8.32%
|
Price to Book
|
1.21
x
|
1.05
x
|
1.01
x
|
0.95
x
|
0.91
x
|
0.74
x
|
0.7
x
|
0.67
x
|
Nbr of stocks (in thousands)
|
136,110
|
136,491
|
133,774
|
134,640
|
135,506
|
136,320
|
-
|
-
|
Reference price
2 |
51.66
|
44.72
|
38.90
|
34.09
|
32.18
|
27.53
|
27.53
|
27.53
|
Announcement Date
|
27/02/20
|
01/03/21
|
01/03/22
|
27/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4,837
|
5,063
|
4,139
|
4,452
|
4,656
|
4,623
|
4,833
|
5,010
|
EBITDA
1 |
894.4
|
885.6
|
578
|
576.9
|
663.9
|
715.9
|
811.1
|
850.5
|
EBIT
1 |
809.2
|
795.8
|
479
|
492.3
|
574.3
|
610.5
|
712.3
|
781
|
Operating Margin
|
16.73%
|
15.72%
|
11.57%
|
11.06%
|
12.34%
|
13.21%
|
14.74%
|
15.59%
|
Earnings before Tax (EBT)
1 |
171
|
-
|
-
|
-139.1
|
-8.3
|
-139.2
|
138.8
|
266.4
|
Net income
1 |
146.1
|
-162.6
|
-68.9
|
-140.6
|
-12.7
|
-74.25
|
106.4
|
208.2
|
Net margin
|
3.02%
|
-3.21%
|
-1.66%
|
-3.16%
|
-0.27%
|
-1.61%
|
2.2%
|
4.16%
|
EPS
2 |
1.070
|
-1.190
|
-0.5200
|
-1.040
|
-0.0900
|
-1.450
|
0.1600
|
1.140
|
Free Cash Flow
1 |
250.1
|
465.8
|
4
|
210.9
|
303.8
|
467
|
511
|
546
|
FCF margin
|
5.17%
|
9.2%
|
0.1%
|
4.74%
|
6.53%
|
10.1%
|
10.57%
|
10.9%
|
FCF Conversion (EBITDA)
|
27.96%
|
52.6%
|
0.69%
|
36.56%
|
45.76%
|
65.23%
|
63%
|
64.2%
|
FCF Conversion (Net income)
|
171.18%
|
-
|
-
|
-
|
-
|
-
|
480.04%
|
262.25%
|
Dividend per Share
2 |
0.8200
|
0.9000
|
0.9600
|
1.040
|
1.090
|
1.102
|
1.172
|
1.263
|
Announcement Date
|
27/02/20
|
01/03/21
|
01/03/22
|
27/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1,105
|
1,074
|
1,122
|
1,100
|
1,155
|
1,182
|
1,193
|
1,124
|
1,157
|
1,082
|
1,163
|
1,163
|
1,215
|
1,149
|
1,201
|
EBITDA
1 |
153.3
|
107.4
|
136.7
|
153.3
|
178.7
|
142.7
|
161.5
|
173
|
186.6
|
115.7
|
156.3
|
194.3
|
208.2
|
194.7
|
207.8
|
EBIT
1 |
131.5
|
86.8
|
116.4
|
133
|
156
|
119.6
|
137.3
|
150.3
|
167.1
|
93
|
140.2
|
177.4
|
200.3
|
172.4
|
179.5
|
Operating Margin
|
11.9%
|
8.08%
|
10.38%
|
12.09%
|
13.5%
|
10.12%
|
11.51%
|
13.37%
|
14.44%
|
8.59%
|
12.06%
|
15.25%
|
16.48%
|
15%
|
14.94%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-3.5
|
-14.3
|
4.3
|
-
|
-
|
-54.4
|
-98.6
|
-37.65
|
-8.65
|
5.95
|
53.4
|
60.1
|
Net income
1 |
-
|
-
|
-
|
-49.4
|
-23.7
|
-
|
8.4
|
-
|
-32.3
|
2
|
-27.1
|
-6
|
-43.1
|
40.3
|
45.7
|
Net margin
|
-
|
-
|
-
|
-4.49%
|
-2.05%
|
-
|
0.7%
|
-
|
-2.79%
|
0.18%
|
-2.33%
|
-0.52%
|
-3.55%
|
3.51%
|
3.8%
|
EPS
|
-
|
-
|
-
|
-0.3700
|
-0.1700
|
-0.0200
|
0.0600
|
-
|
-0.2400
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.2400
|
0.2600
|
0.2600
|
0.2600
|
0.2600
|
0.2700
|
0.2700
|
0.2700
|
0.2800
|
-
|
0.2800
|
0.2800
|
0.2800
|
-
|
-
|
Announcement Date
|
01/03/22
|
11/05/22
|
09/08/22
|
08/11/22
|
27/02/23
|
09/05/23
|
08/08/23
|
07/11/23
|
27/02/24
|
07/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
3,015
|
2,925
|
1,656
|
3,506
|
3,322
|
3,209
|
3,012
|
2,813
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
3.371
x
|
3.302
x
|
2.864
x
|
6.077
x
|
5.004
x
|
4.482
x
|
3.713
x
|
3.308
x
|
Free Cash Flow
1 |
250
|
466
|
4
|
211
|
304
|
467
|
511
|
546
|
ROE (net income / shareholders' equity)
|
9.58%
|
9.74%
|
5.14%
|
5.62%
|
7.33%
|
7.15%
|
8.37%
|
8.75%
|
ROA (Net income/ Total Assets)
|
1.31%
|
-1.43%
|
2.53%
|
2.62%
|
3.23%
|
3.28%
|
4.05%
|
4.38%
|
Assets
1 |
11,142
|
11,395
|
-2,720
|
-5,366
|
-393.7
|
-2,264
|
2,630
|
4,757
|
Book Value Per Share
2 |
42.60
|
42.50
|
38.50
|
35.90
|
35.20
|
37.30
|
39.10
|
40.90
|
Cash Flow per Share
|
2.840
|
-
|
-
|
-
|
3.000
|
-
|
-
|
-
|
Capex
1 |
138
|
170
|
152
|
96.4
|
102
|
113
|
118
|
123
|
Capex / Sales
|
2.85%
|
3.37%
|
3.68%
|
2.17%
|
2.18%
|
2.44%
|
2.43%
|
2.45%
|
Announcement Date
|
27/02/20
|
01/03/21
|
01/03/22
|
27/02/23
|
27/02/24
|
-
|
-
|
-
|
Last Close Price
27.53
USD Average target price
39.5
USD Spread / Average Target +43.48% Consensus |
1st Jan change
|
Capi.
|
---|
| +42.87% | 739B | | +32.34% | 598B | | -6.08% | 353B | | +17.36% | 318B | | +3.35% | 285B | | +16.47% | 240B | | +9.26% | 210B | | -5.07% | 206B | | +5.75% | 164B |
Other Pharmaceuticals
|